Lei Wang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6310704/publications.pdf

Version: 2024-02-01

28	878	471509 17	501196 28
papers	citations	h-index	g-index

29	29	29	1262
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Targeting the HSP90â€“CDC37â€“kinase chaperone cycle: A promising therapeutic strategy for cancer. Medicinal Research Reviews, 2022, 42, 156-182.	10.5	32
2	Methods for the Discovery and Identification of Small Molecules Targeting Oxidative Stress-Related Proteinâ€“Protein Interactions: An Update. Antioxidants, 2022, 11, 619.	5.1	6
3	Discovery of Clinical Candidate NTQ1062 as a Potent and Bioavailable Akt Inhibitor for the Treatment of Human Tumors. Journal of Medicinal Chemistry, 2022, 65, 8144-8168.	6.4	7
4	Beyond Proteolysis-Targeting Chimeric Molecules: Designing Heterobifunctional Molecules Based on Functional Effectors. Journal of Medicinal Chemistry, 2022, 65, 8091-8112.	6.4	25
5	Design, synthesis and bioevaluation of inhibitors targeting HSP90-CDC37 protein-protein interaction based on a hydrophobic core. European Journal of Medicinal Chemistry, 2021, 210, 112959.	5.5	8
6	Discovery of a covalent inhibitor of heat shock protein 90 with antitumor activity that blocks the co-chaperone binding via C-terminal modification. Cell Chemical Biology, 2021, 28, 1446-1459.e6.	5.2	8
7	Strategies for Targeting Serine/Threonine Protein Phosphatases with Small Molecules in Cancer. Journal of Medicinal Chemistry, 2021, 64, 8916-8938.	6.4	14
8	Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions. Journal of Medicinal Chemistry, 2020, 63, 1798-1822.	6.4	117
9	Modulation of protein fate decision by small molecules: targeting molecular chaperone machinery. Acta Pharmaceutica Sinica B, 2020, 10, 1904-1925.	12.0	19
10	Discovery and Optimization of Small Molecules Targeting the Proteinâ€“Protein Interaction of Heat Shock Protein 90 (Hsp90) and Cell Division Cycle 37 as Orally Active Inhibitors for the Treatment of Colorectal Cancer. Journal of Medicinal Chemistry, 2020, 63, 1281-1297.	6.4	24
11	Design, Synthesis, and Biological Evaluation of HSP90 Inhibitorâ€“SN38 Conjugates for Targeted Drug Accumulation. Journal of Medicinal Chemistry, 2020, 63, 5421-5441.	6.4	11
12	Small-molecule inhibitor targeting the Hsp90-Cdc37 protein-protein interaction in colorectal cancer. Science Advances, 2019, 5, eaax2277.	10.3	57
13	Structure-activity and structure-property relationships of novel Nrf2 activators with a 1,2,4-oxadiazole core and their therapeutic effects on acetaminophen (APAP)-induced acute liver injury. European Journal of Medicinal Chemistry, 2018, 157, 1376-1394.	5.5	23
14	3-(1H-Benzo[d]imidazol-6-yl)-5-(4-fluorophenyl)-1,2,4-oxadiazole (DDO7232), a Novel Potent Nrf2/ARE Inducer, Ameliorates DSS-Induced Murine Colitis and Protects NCM460 Cells against Oxidative Stress via ERK1/2 Phosphorylation. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-16.	4.0	11
15	Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction. European Journal of Medicinal Chemistry, 2017, 136, 63-73.	5.5	36
16	Optimization and bioevaluation of Cdc37-derived peptides: An insight into Hsp90-Cdc37 protein-protein interaction modulators. Bioorganic and Medicinal Chemistry, 2017, 25, 233-240.	3.0	16
17	Targeting Hsp90-Cdc37: A Promising Therapeutic Strategy by Inhibiting Hsp90 Chaperone Function. Current Drug Targets, 2017, 18, 1572-1585.	2.1	15
18	Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5. European Journal of Medicinal Chemistry, 2016, 118, 1-8.	5.5	38

#	Article	IF	Citations
19	Betulinic acid acetate, an antiproliferative natural product, suppresses client proteins of heat shock protein pathways through a CDC37-binding mechanism. RSC Advances, 2016, 6, 42537-42544.	3.6	2
20	Optimization and biological evaluation of celastrol derivatives as Hsp90â€“Cdc37 interaction disruptors with improved druglike properties. Bioorganic and Medicinal Chemistry, 2016, 24, 5431-5439.	3.0	39
21	Novel nitric oxide-releasing spirolactone-type diterpenoid derivatives with in vitro synergistic anticancer activity as apoptosis inducer. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4191-4196.	2.2	16
22	Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90. Journal of Medicinal Chemistry, 2016, 59, 10498-10519.	6.4	32
23	Natural Product Kongensin A is a Non-Canonical HSP90 Inhibitor that Blocks RIP3-dependent Necroptosis. Cell Chemical Biology, 2016, 23, 257-266.	5.2	85
24	NRF2 promotes breast cancer cell proliferation and metastasis by increasing RhoA/ROCK pathway signal transduction. Oncotarget, 2016, 7, 73593-73606.	1.8	101
25	Discovery and identification of Cdc37-derived peptides targeting the Hsp90â€“Cdc37 proteinâ€“protein interaction. RSC Advances, 2015, 5, 96138-96145.	3.6	20
26	Effective Screening Strategy Using Ensembled Pharmacophore Models Combined with Cascade Docking: Application to p53-MDM2 Interaction Inhibitors. Journal of Chemical Information and Modeling, 2013, 53, 2715-2729.	5.4	23
27	Synthesis of spirolactone-type diterpenoid derivatives from kaurene-type oridonin with improved antiproliferative effects and their apoptosis-inducing activity in human hepatoma Bel-7402 cells. European Journal of Medicinal Chemistry, 2013, 59, 322-328.	5.5	33
28	The conversion of oridonin to spirolactone-type or enmein-type diterpenoid: Synthesis and biological evaluation of ent-6,7-seco-oridonin derivatives as novel potential anticancer agents. European Journal of Medicinal Chemistry, 2012, 52, 242-250.	5.5	60